natgillin/translations-raw huggingface dataset:
The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are: 
Drugi neželeni učinki, ki so se pojavili nekaterim bolnikom med jemanjem pioglitazona z drugimi zdravili za sladkorno bolezen, so:
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. 
Boljša urejenost glikemije je povezana z zmanjšanjem koncentracije insulina v plazmi na tešče in po obrokih.
1 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. 
V poročilih po pridobitvi dovoljenja za promet so poročali o preobčutljivostnih reakcijah pri bolnikih zdravljenih s pioglitazonom.
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98 and 100 tablets. 
Aluminijski/aluminijski pretisni omoti, pakiranja s 14, 28, 30, 50, 56, 84, 90, 98 in 100 tabletami.
Proportional increases of the plasma concentration were observed for doses from 2-60 mg. 
Pri odmerkih od 2 do 60 mg so opazili sorazmerno povečanje koncentracije v plazmi.
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. 
V študiji kardiovaskularnih izidov PROactive so 5238 bolnikov s sladkorno boleznijo tipa 2 in obstoječo hudo makrovaskularno boleznijo za obdobje do 3,5 leta randomizirali na pioglitazon ali placebo (oba kot dodatek dotedanjemu antidiabetičnemu in kardiovaskularnemu zdravljenju).
Liver enzymes should be checked prior to the initiation of therapy with pioglitazone in all patients. 
Jetrne encime je treba pred začetkom zdravljenja s pioglitazonom kontrolirati pri vseh bolnikih.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Glidipion. 
Obstaja lahko večja možnost, da zanosite, ker se lahko ob uporabi zdravila Glidipion znova pojavi ovulacija (sprostitev jajčeca).
The packs with 14, 28, 56, 84 and 98 tablets contain blisters with abbreviations for days of the week printed on the blister (Mon., Tue., Wed., Thu., Fri., Sat., Sun.). 
Pakiranja s 14, 28, 56, 84 in 98 tabletami vsebujejo pretisne omote, na katerih so natisnjene okrajšave za dneve v tednu (PON, TOR, SRE, ČET, PET, SOB, NED).
Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. 
Visceralno maščevje se je značilno zmanjšalo, masa zunajtrebušnega maščevja pa se je povečala.
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy, thereby reducing the availability of metabolic substrates for foetal growth. 
To je mogoče pripisati vplivu pioglitazona na zmanjšanje hiperinsulinemije pri materi in večji odpornosti proti insulinu, ki se pojavi med nosečnostjo; to zmanjša dostopnost presnovnih substratov za rast plodu.
If you forget to take Glidipion 
Če ste pozabili vzeti zdravilo Glidipion
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
V 3,5-letni študiji PROactive je imelo zlom 44 od 870 (5,1 %) žensk, zdravljenih s pioglitazonom, in 23 od 905 (2,5 %) žensk, zdravljenih s primerjalnim zdravilom.
Repeated dosing does not result in accumulation of the compound or metabolites. 
Večkratno odmerjanje ne povzroči kopičenja pioglitazona ali njegovih presnovkov.
3 In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. 
V kontroliranih kliničnih preskušanjih je bila incidenca srčnega popuščanja med zdravljenjem s pioglitazonom enaka kot med prejemniki placeba, metformina in sulfonilsečnine, večja pa je bila med uporabo v kombiniranem zdravljenju z insulinom.
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, 
- če imate diabetično ketoacidozo (zaplet sladkorne bolezni, ki povzroči hitro izgubljanje telesne mase, slabost v želodcu ali bruhanje).
If you stop taking Glidipion 
Če ste prenehali jemati zdravilo Glidipion
Not all the pack sizes may be marketed. 
Na trgu ni vseh navedenih pakiranj.
Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment. 
Bolnikom je treba naročiti, da morajo v primeru makroskopske hematurije ali drugih simptomov (npr. dizurije ali nuje za uriniranje), ki se pojavijo med zdravljenjem, takoj obiskati zdravnika.
Each tablet contains 113.31 mg of lactose monohydrate (see section 4.4). 
Ena tableta vsebuje 113,31 mg laktoza monohidrata (glejte poglavje 4.4).
What you need to know before you take Glidipion Do not take Glidipion 
Kaj morate vedeti, preden boste vzeli zdravilo glidipion
The tablets are supplied in aluminium blister packs of 14, 28, 30, 50, 56, 84, 90, 98 and 100 tablets. 
Tablete so na voljo v aluminijskih pretisnih omotih s 14, 28, 30, 50, 56, 84, 90, 98 ali 100 tabletami.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
Podobne spremembe so opažali v primerjalnih kontroliranih preskušanjih s pioglitazonom pri bolnikih, zdravljenih z metforminom (relativno znižanje hemoglobina za 3-4 % in hematokrita za 3,6-4,1 %), in v manjši meri pri bolnikih, zdravljenih s sulfonilsečnino in insulinom (relativno znižanje hemoglobina za 1-2 % in hematokrita za 1- 3,2 %).
In vitro studies have shown no inhibition of any subtype of cytochrome P450. 
Študije in vitro niso pokazale zavrtja nobenega podtipa citokroma P450.
Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). 
Pioglitazon je treba uporabljati previdno med sočasnim zdravljenjem z zaviralci citokroma P450 2C8 (npr. z gemfibrozilom) ali njegovimi induktorji (npr. z rifampicinom).
In vitro studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. 
Študije in vitro niso pokazale, da bi pioglitazon zaviral katerokoli podvrsto citokroma P450.
Pioglitazone will not affect your ability to drive or use machines but take care if you experience abnormal vision. 
Vpliv na sposobnost upravljanja vozil in strojev Pioglitazon ne bo vplival na vašo sposobnost upravljanja vozil in strojev, vendar pa morate biti pazljivi, če se vam pojavi zamegljen vid.
In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year. 
V dveletni študiji kombiniranega zdravljenja, ki je primerjala pioglitazon z gliklazidom, dodanima metforminu, je bila urejenost glikemije (merjena kot povprečna sprememba HbA1c od izhodišča) po enem letu v obeh terapevtskih skupinah podobna.
In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those ≥65 years compared to 4.0% in patients less than 65 
Pri bolnikih, ki so se zdravili samo z insulinom, brez pioglitazona, je odstotek srčnega popuščanja pri bolnikih, starih 65 let in starejših, znašal 8,2 %, pri bolnikih, mlajših od 65 let, pa 4,0 %.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
POGOJI IN OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - okužba dihal - nenormalen vid - povečanje telesne mase - omrtvelost
The usual starting dose is one tablet of 15 mg or 30 mg of pioglitazone to be taken once daily. 
Običajni začetni odmerek je ena 15-miligramska ali 30-miligramska tableta pioglitazona enkrat na dan.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
V večini kliničnih preskušanj so v primerjavi s placebom opažali zmanjšanje celotne koncentracije trigliceridov in prostih maščobnih kislin v plazmi ter povečanje koncentracije holesterola HDL, z majhnimi, a klinično ne pomembnimi povečanji koncentracije holesterola LDL.
Heart failure has been experienced commonly (up to 1 in 10 people) in patients taking pioglitazone in combination with insulin. 
Srčno popuščanje je bilo pogosto (pojavi se lahko pri največ 1 od 10 bolnikov) med bolniki, ki so prejemali pioglitazon v kombinaciji z insulinom.
Carmellose calcium Hydroxypropylcellulose Lactose monohydrate Magnesium stearate 
6.1 Seznam pomožnih snovi kalcijev karmelozat hidroksipropilceluloza laktoza monohidrat magnezijev stearat
Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. 
Pioglitazon v primerjavi s placebom ni statistično značilnih zvišal koncentracije holesterola LDL, z metforminom in gliklazidom pa so zabeležili njeno znižanje.
The risk of fractures should be considered in the long term care of patients treated with pioglitazone (see section 4.8). 
Pri dolgoročnem zdravljenju bolnikov s pioglitazonom je treba upoštevati tveganje zlomov (glejte poglavje 4.8).
The other side effects that have been experienced by some patients taking pioglitazone: 
Drugi neželeni učinki, ki so se pojavili nekaterim bolnikom med uporabo pioglitazona, so:
There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). 
Med postmarketinškim obdobjem so poročali o redkih primerih motenega delovanja jetrnih celic (glejte poglavje 4.8).
Skin and subcutaneous tissue disorders sweating uncommon 
Bolezni kože in podkožja znojenje občasno
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
V 3,5-letni študiji kardiovaskularnega tveganja PROactive se je zlom pojavil pri 44 od 870 (5,1 %, 1,0 zlom na 100 bolnik-let) žensk, zdravljenih s pioglitazonom, in pri 23 od 905 (2,5 %, 0,5 zloma na 100 bolnik-let) žensk, zdravljenih s primerjalnim zdravilom.
If you experience any of these, talk to your doctor as soon as possible. 
Če se vam pojavi kateri od teh, se čim prej posvetujte z zdravnikom.
Each tablet contains 37.77 mg of lactose monohydrate (see section 4.4). 
Ena tableta vsebuje 37,77 mg laktoza monohidrata (glejte poglavje 4.4).
Each tablet contains 75.54 mg of lactose monohydrate (see section 4.4). 
Ena tableta vsebuje 75,54 mg laktoza monohidrata (glejte poglavje 4.4).
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. 
Opravljena je bila kumulativna analiza neželenih učinkov zlomov kosti iz randomiziranih, s primerjalnim zdravilom kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8100 bolnikih, zdravljenih s pioglitazonom, in 7400 bolnikih, ki so prejemali primerjalna zdravila, v obdobju do 3,5 leta.
How to take Glidipion 
Kako jemati zdravilo glidipion
In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. 
V 20-tedenski študiji je pioglitazon znižal raven trigliceridov na tešče, pa tudi hipertrigliceridemijo po obroku, in sicer z vplivom absorpcijo trigliceridov in njihovo sintezo v jetrih.
Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. 
Zlome so opazili pri 2,6 % žensk, ki so prejemale pioglitazon, in pri 1,7 % žensk, ki so prejemale primerjalno zdravilo.
as triple oral therapy in combination with - metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. 
Kot tritirno peroralno zdravljenje v kombinaciji - z metforminom in sulfonilsečnino pri odraslih bolnikih (zlasti bolnikih s čezmerno telesno maso), ki glikemije nimajo zadostno urejene kljub dvotirnemu peroralnemu zdravljenju.
Localised swelling (oedema) has also been experienced very commonly in patients taking pioglitazone in combination with insulin. 
Omejeno otekanje (edemi) je bilo med bolniki, ki so prejemali pioglitazon v kombinaciji z insulinom, zelo pogosto.
There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months. 
Hiperplazije sečnega mehurja niso opazili pri psih ali opicah, ki so prejemali pioglitazon do 12 mesecev.
- a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. 
- s sulfonilsečnino, le pri odraslih bolnikih, ki metformina ne prenesejo ali je pri njih kontraindiciran, glikemije pa nimajo zadostno urejene kljub največjemu tolreriranemu odmerku sulfonilsečnine v monoterapiji.
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
Med zdravljenjem s pioglitazonom so ugotovili majhno znižanje povprečne koncentracije hemoglobina (4 % relativno znižanje) in majhno znižanje hematokrita (4,1 % relativno znižanje), ki se skladata s hemodilucijo.
very common fatigue uncommon 
Edemi zelo pogosto utrujenost občasno
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. 
V toksikoloških študijah so po večkratnem odmerjanju pri miših, podganah, psih in opicah dosledno opažali povečanje volumna plazme s hemodilucijo, anemijo in reverzibilno ekscentrično hipertrofijo srca.
Uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - vnetje obnosnih votlin (sinuzitis) - težave s spanjem (nespečnost)
On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal. 
Upoštevaje aktivnost, koncentracijo in vezavo na beljakovine k aktivnosti v enaki meri prispevata pioglitazon in presnovek M-III. Na tej podlagi prispeva M-IV k učinkovitosti približno trikrat toliko kot pioglitazon, relativna učinkovitost M-II pa je minimalna.
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. 
Spodaj so po organskem sistemu in absolutni pogostnosti s prednostnimi izrazi MedDRA navedeni neželeni učinki, ki so jih v dvojno slepih študijah pri prejemnikih pioglitazona zabeležili pogosteje (> 0,5 %) kot s placebom in so bili pogostejši kot le posamezni primeri.
as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. 
Kot dvotirno peroralno zdravljenje v kombinaciji - z metforminom pri odraslih bolnikih (zlasti bolnikih s čezmerno telesno maso), ki glikemije nimajo zadostno urejene kljub največjemu toleriranemu odmerku metformina v monoterapiji.
Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. 
Zdravljenje s pioglitazonom se lahko začne s 15 mg ali 30 mg enkrat na dan. Odmerek je mogoče postopoma povečevati do 45 mg enkrat na dan.
- if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of Glidipion 
Ne jemljite zdravila Glidipion - če ste preobčutljivi za (alergični na) pioglitazon ali katero koli sestavino zdravila Glidipion (za seznam sestavin glejte poglavje 6).
Each tablet contains 15 mg, 30 mg or 45 mg of pioglitazone (as hydrochloride). 
Ena tableta vsebuje 15 mg, 30 mg ali 45 mg pioglitazona (kot klorida).
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
V preskušanjih, kontroliranih s primerjalnim zdravilom, je bilo povprečno povečanje telesne mase s pioglitazonom v monoterapiji od 2 do 3 kg v enem letu.
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. 
Bolnike, zlasti tiste z zmanjšano srčno rezervo, je treba spremljati glede znakov in simptomov srčnega popuščanja, povečanja telesne mase ali edemov.
If you experience this symptom for the first time, talk to your doctor as soon as possible. 
Če se vam ta simptom pojavi prvi, se čim prej posvetujte z zdravnikom.
Foetal growth restriction was apparent in animal studies with pioglitazone. 
V študijah pioglitazona na živalih so opažali omejitev rasti ploda.
Metabolism and nutrition disorders hypo-glycaemia uncommon very common common appetite increased uncommon 
Presnovne in prehranske motnje hipoglikemija občasno zelo pogosto pogosto povečanje apetita občasno
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5). 
Sočasna uporaba pioglitazon z gemfibrozilom (zaviralec citokroma P450 2C8) oz. rifampicina (induktor citokroma P450 2C8) je povečala (gemfibrozil) oz. zmanjšala (rifampicin) koncentracijo pioglitazona v plazmi (glejte poglavje
Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible. 
Prav tako se čim prej posvetujte z zdravnikom, če ste že imeli zamegljen vid, pa se vam ta simptom poslabša.
Marketing Authorisation Holder Actavis Group PTC ehf. 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Actavis Group PTC ehf.
Respiratory, thoracic and mediastinal disorders dyspnoea common 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja pogosto
Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been reported in patients taking pioglitazone. 
Pri bolnikih, ki so prejemali pioglitazon, je bil opisan tudi zamegljen vid zaradi otekline (ali tekočine) v zadnjem delu očesa (pogostnost ni znana).
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Opisano je, da sočasna uporaba pioglitazona z rifampicinom (induktor citokroma P450 2C8) zmanjša AUC pioglitazona za 54 %.
Glidipion 15 mg, 30 mg and 45 mg tablets Glidipion 15 mg tablets 
Glidipion 15 mg, 30 mg in 45 mg tablete Glidipion 15 mg tablete
common common uncommon macular oedema not known not known not known not known not known 
Očesne bolezni motnje vida pogosto pogosto občasno edem makule ni znano ni znano ni znano ni znano ni znano
In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL cholesterol levels, compared with placebo, metformin or gliclazide. 
V kliničnih preskušanjih, ki so trajala do dve leti, je pioglitazon v primerjavi s placebom, metforminom ali gliklazidom znižal celotno koncentracijo plazemskih trigliceridov in prostih maščobnih kislin v plazmi ter povečal koncentracijo holesterola HDL.
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Med postmarketinškim obdobjem so bili opisani primeri srčnega popuščanja med uporabo pioglitazona v kombinaciji z insulinom ali pri bolnikih z anamnezo srčnega popuščanja.
The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. 
Med sočasno uporabo z rifampicinom utegne biti potrebno povečanje odmerka pioglitazona.
Glidipion may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar. 
Zdravilo Glidipion lahko uporabljamo samo pri bolnikih, ki ne morejo jemati metformina, in ko zdravljenje z dieto in telesno vadbo ni uspešno pri nadzoru krvnega sladkorja.
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. 
Poročali so, da sočasna uporaba pioglitazona in gemfibrozila (zaviralec citokroma P450 2C8) povzroči 3-kratno povečanje AUC pioglitazona.
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC,ODGOVOREN ZA SPROŠČANJE SERIJE
Allergic reactions have been reported (frequency not known) in patients taking Glidipion. 
Pri bolnikih, ki jemljejo zdravilo Pioglitazon Actavis, so poročali o alergijskih reakcijah (pogostnost ni znana).
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Glidipion. 
Zdravilo Glidipion vsebuje laktozo monohidrat Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se z njim posvetujte, preden vzamete to zdravilo Glidipion.
What is in this leaflet: 
Navodilo vsebuje:
Broken bones have been reported commonly (up to 1 in 10 people) in female patients taking pioglitazone and have also been reported in male patients (frequency cannot be estimated from the available data) taking pioglitazone. 
O zlomih so poročali tudi pri bolnikih, ki so se zdravili z zdravilom Actos (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03. 
insulin; oznaka ATC: A10BG03.
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). 
Pri moških, zdravljenih s pioglitazonom, niso opazili večjega deleža zlomov (1,7 %) kot s primerjalnim zdravilom (2,1 %).
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years. 
V kumulativni analizi neželenih učinkov zlomov kosti iz randomiziranih, kontroliranih, dvojno slepih kliničnih preskušanj pri več kot 8100 s pioglitazonom in 7400 s primerjalnim zdravilom zdravljenih bolnikih, zdravljenih do 3,5 leta, so opazili večjo incidenco zlomov kosti pri ženskah.
Bladder cancer has been experienced uncommonly (up to 1 in 100 people) in patients taking pioglitazone. 
Rak mehurja je bil med bolniki, ki so prejemali pioglitazon, občasen (pojavi se lahko pri največ 1 od 100 bolnikov).
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). 
Večji delež zlomov so opažali pri ženskah, ki so prejemale pioglitazon (2,6 %), kot pri ženskah, ki so prejemale primerjalno zdravilo (1,7 %).